Regulus
The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.
The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.
The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.
Regulus Hits Milestone in Biogen Idec microRNA Biomarker Deal
Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner.
The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.
Nov 24, 2014
Nov 6, 2014
Nov 6, 2014
Nov 6, 2014
Oct 30, 2014
Oct 23, 2014
Sep 25, 2014
Aug 21, 2014
Aug 7, 2014
Jul 24, 2014
Jun 26, 2014
Jun 26, 2014
Jun 12, 2014
May 15, 2014
Apr 10, 2014
Mar 6, 2014
Feb 20, 2014